DUBLIN--(BUSINESS WIRE)--The "Global Flow Cytometry Market by Technology (Cell-based, Bead-based), Product & Service (Analyzer, Sorter, Consumables, Software), Application ((Research - Immunology, Stem cell), (Clinical - Hematology)), End user (Biotech, Hospitals) - Forecast to 2027" report has been added to ResearchAndMarkets.com's offering.
The global flow cytometry market is projected to reach USD 6.9 billion by 2027 from USD 4.7 billion in 2022, at a CAGR of 8.1%
The rising prevalence of HIV/AIDS, cancer & autoimmune diseases across the globe is increasing the adoption of flow cytometry for diagnosis hence projecting market growth. Additionally, the launch of technologically advent products is furthermore likely to propel the market growth during the forecast period of 2022-2027.
Instruments segment held a substantial share in the global flow cytometry market in 2021.
Based on products & services, the market is segmented into reagents & consumables, instruments, services, software and accessories. The reagents & consumables segment held a dominant share in the market in 2021 and is anticipated to continue dominance during the forecast period.
The launch of new reagents & consumables in the market which are making research grow at a faster pace is likely to drive segmental growth. In November 2021, Bio-Rad Laboratories, Inc. (US), launched StarBright UltraViolet 400 Dye, fluorescent nanoparticles designed for use with a UV laser in flow cytometry applications.
Research applications segment dominated the market in 2021.
Based on end user, the flow cytometry market is segmented into research applications, clinical applications, and industrial applications.
The strong focus of key market players in the clinical applications of flow cytometry is likely to project segmental growth. For instance, in October 2021, BD (Becton, Dickinson and Company)(US), in collaboration with Christian Medical College Vellore (India) launched its second Center of Excellence (CoE) in flow cytometry for clinical research in India.
North America held a dominant share in 2021.
Geographically, the flow cytometry market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. In 2021, North America accounted for the major share of the flow cytometry market. North America held a dominant share owing to the presence of key market players coupled with increased adoption of flow cytometry in research applications in the region.
The Asia Pacific is expected to grow at a faster pace due to increased research funding and adoption of flow cytometry in clinical applications.
Competitive landscape
The prominent players in the flow cytometry market are Becton, Dickinson and Company (US), Danaher Corporation (US), Thermo Fisher Scientific, Inc. (US), Agilent Technologies, Inc. (US), and Luminex Corporation (US).
Premium Insights
- Increasing Prevalence of Autoimmune Diseases and Rising Advancements in Flow Cytometry Techniques Drive Market Growth
- Reagents & Consumables Segment Accounted for Largest Share in 2021
- Cell-based Flow Cytometry Segment to Dominate Market During Forecast Period
- China to Register Highest Growth During Forecast Period
Market Dynamics
Drivers
- Increasing Incidence of HIV/Aids and Cancer
- Flow Cytometry Techniques in Research Activities
- Use of Flow Cytometry in Regenerative Medicine
- Growing Public-Private Initiatives in Immunology and Immuno-Oncology Research
- Technological Advancements in Flow Cytometry Instruments
Restraints
- High Product Cost
Opportunities
- Emerging Markets
- Public-Private Funding Initiatives in Stem Cell Research
- Adoption of Recombinant DNA Technology for Antibody Production
Challenges
- Complexities Related to Reagent Development
- Shortage of Well-Trained and Skilled Professionals
Patent Analysis
Value Chain Analysis
- Ecosystem Analysis
- Role in Ecosystem
Regulatory Assessment
- Stringent FDA Requirements
- Analyte-Specific Reagent Rule
- Limitations in Validation Protocols for Cell-based Assays
- Absence of Test Guidelines on Cell-based Fluorescence Assays
- IVD Ce Mark Approvals
US: Reimbursement Scenario
Company Profiles
Key Players
- BD
- Danaher Corporation
- Thermo Fisher Scientific, Inc.
- Agilent Technologies, Inc.
- Sony Biotechnology Inc. (A Subsidiary of Sony Group Corporation)
- Bio-Rad Laboratories Inc.
- Miltenyi Biotec
- Enzo Biochem, Inc.
- Sysmex Corporation
- Luminex Corporation (A Diasorin Company)
- Biomerieux SA
- Cytonome/St, LLC.
- Sartorius AG
- Cytek Biosciences
- Union Biometrica, Inc.
Other Players
- Apogee Flow Systems Ltd.
- Stratedigm, Inc.
- Nanocellect Biomedical, Inc.
- On-Chip Biotechnologies Co. Ltd.
- Nexcelom Bioscience LLC.
- Bennubio Inc.
- Orflo Technologies
- Bay Bioscience Co. Ltd.
- Cytobuoy B.V.
- Biolegend, Inc.
For more information about this report visit https://www.researchandmarkets.com/r/6luffi
